Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q3 EPS of ($0.72), $0.09 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $1.27 million versus the consensus estimate of $11.16 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.